Intraosseous Basivertebral Nerve Ablation

LCD Information Document Information Source LCD ID N/A LCD ID L39642 Original ICD-9 LCD ID Not Applicable LCD Title Intraosseous Basivertebral Nerve Ablation Proposed LCD in Comment Period N/A Source Proposed LCD DL39642 Opens in a new window Original Effective Date For services performed on or after 01/28/2024 Revision Effective Date For services performed on or after 03/05/2026 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 12/14/2023 Notice Period End Date 01/27/2024 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Section 1862(a)(1)(A) of Title XVIII of the Social Security Act excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. Section 1833(e) of Title XVIII of the Social Security Act prohibits Medicare payment for any claim which lacks the necessary information to process the claim. CMS Manual System. Publication 100-2, Medicare Benefit Policy Manual, Chapter 15, §80 describes coverage for physician supervision of diagnostic x-ray, lab and other diagnostic tests. Coverage Indications, Limitations, and/or Medical Necessity Coverage Indications, Contraindications, Medical Necessity, Non-Coverage and Limitations Covered Indications Thermal ablation of the intraosseous Basivertebral Nerve (BVN) is considered medically reasonable and necessary for the treatment of Chronic Low Back Pain (CLBP) in patient who meet ALL the following criteria for coverage and reimbursement. Individual is skeletally mature and has had CLBP for at least 6 months, with lower back pain as the dominant symptom. Has failed to adequately improve despite documented non-surgical management, to include at least 3 or more of the following modalities: Avoidance of activities that aggravate pain. Course of physical therapy or professionally directed therapeutic exercise program. Chiropractic manipulation Cognitive therapy Pharmacotherapy, including narcotic and non-narcotic analgesics, muscle relaxants, neuroleptics, and anti-inflammatories. Injection therapy of epidural or facet joint implicated pain sources in the region of concern Type 1 or Type 2 Modic changes on MRI: Endplate hypointensity (Type 1) or hyperintensity (Type 2) on T1 images plus hyperintensity on T2 images (Type1) involving the endplates between L3 and S1 Absence of additional vertebral pathology by physical, history, radiologic or clinical assessment including, but not limited to, fracture, tumor, infection, deformity, trauma, or post-surgical change which could cause the patient's symptoms or complicate the procedure and outcome. Physical and psychological assessment of patient’s ability to tolerate and benefit from BVN ablation. Contraindications to BVN Ablation, Medical Necessity and Non-Coverage The following conditions are considered relative contraindications to BVN ablation as suboptimal outcome and adverse exacerbation of symptoms may occur, precluding expected benefit from the procedure. Documentation in the patient’s medical record must explain the precautionary provisions taken for the individual patient to preclude anticipated or potential adverse events secondary to treatment. In the absence of documentation to support the procedure in individuals with the following concomitant conditions, medical necessity cannot be established. These conditions represent contraindication to treatment and render the service not medically appropriate, reasonable and necessary, or eligible for Medicare Coverage and Reimbursement. Skeletal immaturity (<18 years of age) Evidence on imaging (MRI, flexion/extension radiographs, CT) of another etiology for LBP symptoms, including, but not limited to, lumbar spinal stenosis, spondylolisthesis, segmental instability, disc herniation, degenerative scoliosis, facet arthropathy or effusion with clinically suspected facet joint pain. Metabolic bone disease (e.g., osteoporosis with T score <-2.5), treatment of spine fragility fracture, trauma/compression fracture, or spinal primary or metastatic tumor. Active Spine or Systemic Infection Neurogenic claudication, lumbar radiculopathy, radicular pain, nerve impingement or compression (e.g., NHP, stenosis), as primary symptoms. Patients with severe cardiac or pulmonary compromise, systemic vulnerability to bleeding, or concern for further compromise of existing disease. Patients with implantable pulse generators (e.g., pacemakers, defibrillators, or neurostimulator) and other electronic implants, unless type specific precautions are taken to maintain patient safety. Ongoing use or abuse of addictive medications without evidence of potential weaning or decreased use with treatment. Limitations Basivertebral Nerve Ablation is limited to the following: No previous history of BVN ablation at the planned level of treatment. No more than one to two (1-2) vertebral bodies may be treated at a single session. Treatment of no more than 4 vertebral bodies per patient lifetime. Treatment is within the confines of L3-S1 vertebral bodies. Retreatment of a single vertebral body with BVN ablation within the patient's lifetime is not considered reasonable and necessary. Local anesthesia is considered appropriate for the region treated. Mild sedation may be administered by the performing physician or staff under his direction but should not be coded separately. Additional anesthesia services may not be billed separately without documentation of medical necessity. Definitions Chronic Pain/Chronic Low Back Pain: Pain lasting longer than six months in the same location, seemingly resistant to conservative measures. Conservative Measures/ Non-surgical Management: Any single or combination use of medication, physical therapeutic regimens, psychological or cognitive therapy designed by a qualified health care provider to affect relief of a disability or disease, based on a patient’s needs and physical findings. Incidental encounters are not considered therapeutic unless prescribed and monitored for defined purpose, time, and frequency by a qualified practitioner. Functional impairment: A physical, functional or physiologic impairment causing deviation from the normal function of a tissue, organ or body member, resulting in a significant limitation or impairment of the capacity to move, coordinate actions or perform physical activities, demonstrated by difficulty performing physical and motor tasks, independent movement or basic life functions. Modic Changes (Magnetic Resonance Imaging): MRI features consistent with Type 1 or Type 2 Modic changes such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change). Radicular pain or radiculopathy: pain radiating or identified in the path and distribution or dermatomal pattern of a named spinal nerve. Pain that is localized and does not travel in the distribution of an identified spinal nerve and remains axial in location is considered to have a non-radicular pattern. Spinal stenosis: Narrowing of the central spinal canal and /or the foraminal openings through which nerve or neural tissue are located, causing compression and irritation of the involved neural structures. A wide range of symptoms may be present, contributing to back and extremity pain and dysfunction. Summary of Evidence A systematic review of the published literature on the efficacy, effectiveness, and complications associated with BVN ablation for the treatment of chronic low back pain (cLBP) was published by Conger, et al. (2021).1 Evidence was evaluated using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system of appraisal to determine the certainty of the evidence of the effectiveness of intraosseous BVN radiofrequency neurotomy (RFN). The reviewers found moderate-quality evidence that BVN RFN is both an effective treatment compared to sham procedure and superior to continued standard care management for reduction of pain and disability in stringently selected patients with cLBP and corresponding Modic type 1 and 2 changes at a minimum of 3 months. Khalil, et al. (2019), conducted a multicentered RCT that compared the effectiveness of intraosseous radiofrequency (RF) ablation of the BVN to standard care for the treatment of cLBP in a specific subgroup of patients suspected to have vertebrogenic-related symptomatology.8 A total of 140 patients (mean age 50 years) with cLBP of at least 6 months duration, with Modic Type 1 or 2 vertebral endplate changes between L3 and S1, were randomized to undergo either RF ablation of the BVN or continue standard care. Oswestry disability index scores (ODI) were collected at baseline, 3, 6, 9 and 12-months post-procedure. Secondary outcome measures included the visual analog scale (VAS) for pain intensity and responder rates, and quality of life measures (SF-36 and EQ-5D-5L). The primary endpoint was a between-arm comparison of the mean change in ODI from baseline to 3 months post-treatment. At 3 months follow-up, the minimally invasive RF ablation group demonstrated clinically significant improvement of pain and function compared to the standard care group. Treatment success was significantly greater in the RF group (74.5%) compared with patients in the standard care arm (32.7%) [p<.001]. Health-related quality of life outcomes showed a statistically significant difference favoring the RF group. The study was stopped for benefit at 3 months, which followed an interim analysis showing superiority of the intervention arm. This resulted in a high rate of cross-over. Study limitations include the use of a nonstructured standard care control, open label design, and short-term results. In addition, industry funding was a potential source of study bias. Fischgrund, et al. (2018) conducted a prospective randomized double-blind sham-controlled clinical trial that evaluated the safety and efficacy of radiofrequency (RF) ablation of the BVN for treatment of cLBP.3 The trial involved 225 patients with a mean age of 47 years who were diagnosed with cLBP. Participants were randomized to either a sham (78) or treatment intervention (147). Treatment arm patients underwent thermal ablation at the terminus of the BVN using the Intracept® System. Skeletally mature patients with chronic (≥ 6 months), isolated lumbar pain, who had not responded to at least 6 months of non-operative management and had Type 1 or Type 2 Modic changes at 3 or less contiguous levels at L3-S1 on MRI were included in the study. Furthermore, patients were required to have a minimum ODI of 30 points (100-point scale) and a minimum VAS of 4cm (10cm scale). Mean baseline ODI was 42 and mean baseline VAS was 6.7cm. Stringent exclusion criteria were applied, which included: radicular pain, previous lumbar spine surgery, symptomatic spinal stenosis, diagnosed osteoporosis (T<2.5), disc extrusion or protrusion >5mm, spondylolisthesis >2mm at any level, ≥3 Waddell’s signs of Inorganic Behavior, Beck Depression Inventory >24, patients involved in litigation related to back pain or injury, patients receiving disability compensation, and patients currently taking extended-release narcotics. Patients were evaluated at baseline, and at 2 weeks, 6 weeks, and 3, 6, and 12 months post procedure. The primary endpoint was the comparative change in ODI at 3 months. Results showed the mean between group difference was 5.3 points favoring the intervention group. This difference was not clinically significant; however, the responder analysis, based on ODI decrease ≥ 10 points, showed that 75.6% of patients in the treatment arm as compared to 55.3% in the sham control arm exhibited a clinically meaningful improvement at 3 months. Fischgrund, et al. (2019) subsequently reported the 2-year results from their original clinical trial (SMART Trial).4 Originally, patient evaluations, including patient self -assessments, physical and neurological examinations, and safety assessments, were performed out to 12 months. The protocol was subsequently modified to include longer-term follow up to 24 months. Sham control arm patients were also allowed to cross to RF ablation at 12 months. Of the 78 patients in the control arm, 57 (73%) elected to cross over to receive the Intracept® treatment. Overall, 106 participants, who received BVN ablation, were included in the 24-month analysis. Participants exhibited a durable ODI mean improvement (23.4 points) at 24 months compared to the mean improvements observed during their first year of follow up (20.3, 20.8, and 19.8 points at 3, 6, and 12 months, respectively). At 24 months, the previously reported treatment success (75.6% at 3 months) result was sustained with 76.4% of treated patients continuing to receive clinical benefit from BVN ablation. Improvements in the VAS, and the Medical Outcomes Trust Short-Form Health Survey Physical Component Summary were statistically significant compared to baseline at all follow-up time points through 2 years. In 2020, Fischgrund, et al. reported the 5-year outcomes for 100 patients treated with BVN ablation for vertebrogenic cLBP in the SMART randomized control trial (RCT).5 Five-year study results following BVN ablation showed a significant mean reduction in ODI of 25.95 ± 18.54 (60.6%) compared to a baseline of 42.81 (p<0.001). Mean reduction in VAS pain score was 4.38 points (baseline of 6.74, p<0.001). In total, 66% of patients reported a > 50% reduction in pain, 47% reported a > 75% reduction in pain, and 34% of patients reported complete resolution of their pain. Composite responder rate using thresholds of ≥ 15-point ODI and ≥ 2-point VAS for function and pain at 5 years was 75%. Patients reported a high degree of patient satisfaction: 70% rated their condition as improved; 27% reported no change; and 3% reported their condition had worsened. Seventy-nine percent (79%) of patients indicated they would repeat the BVN ablation for the same condition, and 65% reported resumption of their level of activity prior to having low back pain. A prospective, single-arm study performed by Truumees, et al. (2019), observed the effects of intraosseous RF ablation of the BVN for the treatment of vertebrogenic-related cLBP.19 Patients with cLBP of at least 6 months duration and with Modic Type 1 or 2 vertebral endplate changes between L3 and S1 were treated with RF ablation of the BVN in up to four vertebral bodies. Ninety-three percent (93%) of patients achieved a ≥10-point improvement in ODI, and 75% reported ≥20-point improvement. They concluded that minimally invasive RF ablation of the BVN results in a significant improvement in pain and function in this population of real-world patients with chronic vertebrogenic-related LBP. Markman, et al. (2020) evaluated the hypothesis that cLBP patients reporting reduced opioid use have superior functional outcomes following BVN radiofrequency ablation.14 Data were obtained from 225 patients enrolled in a 2:1, randomized, sham-controlled, double-blind trial examining the effects of BVN ablation on cLBP. Patients who demonstrated Modic Type 1 or 2 vertebral endplate changes in one or more L3 to S1 segments and were nonresponsive to a minimum of 6 months of nonsurgical treatment were included in the study. The authors concluded that subjects undergoing BVN ablation reported lower opioid use and had greater improvement in ODI and VAS scores. This post hoc analysis has several limitations including the small subgroup sample size (N=77), the self-reported use of opioids (potential for recall bias), and the exclusion of patients receiving long-acting opioid therapy (potential selection bias). Macadaeg, et al. (2020) conducted a prospective, single arm trial including 48 patients with more than 6 months of cLBP and Type 1 or 2 Modic changes on MRI.13 Patients were followed post-procedure for 12 months using ODI, VAS, EQ-5D-5L and SF-36 patient-reported outcome metrics. Mean reduction in ODI at 12 months was 32.31 +/- 14.07 (p < 0.001) with 88.89% (40/45) patients reporting a ≥ 15 point ODI decrease at 12 months. Mean VAS pain score decrease was 4.31+/-2.51 at 12 months (p < 0.001) and more than 69% reported a 50% reduction in VAS pain scale. Similarly, SF-36 and EQ-5D-5L scores improved 26.27+/-17.19 and 0.22+/-0.15 (each p < 0.001). Limitations include the observational, open label design, relatively small sample size, uncertainty about generalizability, and the risk of bias associated with industry sponsorship. Transforaminal epiduroscopic basivertebral nerve laser ablation was studied by Kim, et al, (2018) who presented a cohort of 14 patients with cLBP greater than 6 months which was unresponsive to at least 4 months of conservative care.9 This cohort included patients with MRI findings of Modic Type 1 or 2 changes and positive confirmatory provocation discography to determine the affected levels. The results of this preliminary, single-arm case series were promising, yet the role of the transforaminal epiduroscopic ablation remains to be further investigated. The International Society for the Advancement of Spine Surgery (ISASS) 2020 guideline – Intraosseous Ablation of the Basivertebral Nerve for the Relief of Chronic Low Back Pain concluded that “The procedure is supported by level 1 evidence including 2 RCTs demonstrating a statistically significant decrease in pain and an improvement in function with outcomes sustained to at least 24 months in a limited number of studies.”11 BVN ablation may be indicated as a treatment option for cLBP for patients that fail nonsurgical treatment and their cLBP is diagnosed using well-established clinical and MRI findings. The American Society of Pain and Neuroscience (ASPN) identified evidence-based guidelines from the available literature for the proper identification and selection of patients with vertebrogenic low back pain for BVN ablation.17 The systematic review was conducted using United States Preventive Services Task Force Criteria Modified for Interventional Spine Procedures and assigned a Grade A rating of the quality of evidence for BVN ablation indicating a high certainty that the net benefit is substantial in appropriately selected individuals. Providence Health Plan submitted a review of peer-reviewed, published clinical evidence suggesting evidence is insufficient to support the clinical utility of basivertebral nerve (BVN) ablation (Intracept procedure) for the treatment of low back pain. One double-blind, randomized controlled trial (RCT) reported that both Intracept and a control sham procedure reduced pain and improved patient functional status at 1-year follow-up; however, this improvement was not clinically significant. Additional studies (1 RCT and 3 case series) concluded that Intracept is more effective than conservative treatment for resolving LBP; however, these studies report too few events and are at too high a risk of bias to be conclusive. Concern was expressed for device manufacturer conflict of interest in publication and financial support of several referenced studies. Support was expressed for NASS guidelines but noted blinded RCTs with long-term follow-up are needed to validate results reported to date and determine the clinical utility of Intracept BVN ablation relative to current gold standard treatments for low back pain. Recommendations were for allowance of no more than one level treatment per session with exclusion of concomitant combination with any other paravertebral injection or intervention. The North American Spine Society (NASS)16 position statement defines appropriate coverage of BVN ablation. BVN is indicated when: Patients are skeletally mature and have CLBP for at least 6 months, and lower back pain is their main symptom. Patients have failed to adequately improve despite attempts at nonsurgical management. Patients have Type 1 or Type 2 Modic changes on MRI — endplate hypo-intensity (Type 1) or hyperintensity (Type 2) on T1 images plus hyperintensity on T2 images (Type 1) involving in the endplates between L3 and S1. BVN ablation is NOT indicated in ANY of the following scenarios: Evidence on imaging (MRI, flexion/extension radiographs, etc.) suggests another obvious etiology for the patient’s LBP symptoms, including but not limited to lumbar stenosis, spondylolisthesis, segmental instability, disc herniation, degenerative scoliosis or facet arthropathy or effusion with clinically suspected facet joint pain. Metabolic bone disease (e.g., osteoporosis), treatment of spine fragility fracture, trauma/compression fracture or spinal cancer. Spine infection or active systemic infection. Neurogenic claudication, lumbar radiculopathy or radicular pain due to neuro-compression (e.g., HNP, stenosis), as primary symptoms. Patients with severe cardiac or pulmonary compromise. Patients with implantable pulse generators (e.g., pacemakers, defibrillators) or other electronic implants unless specific precautions are taken to maintain patient safety. Analysis of Evidence (Rationale for Determination) Chronic low back pain (cLBP) is a major contributor to patient disability and affects a significant portion of Medicare Beneficiaries. Persistent lower back pain lasting longer than 12 weeks is considered Chronic Low Back Pain (cLBP) and is frequently attributed to disease of the intervertebral discs, suggesting sensitized nociceptors in the annulus fibrosus of degenerating discs, etiologic for discomfort or pain. Arthritic processes in and around the spinal vertebral bodies have been implicated for localized tenderness as well as radicular pain due to compression or irritation of adjacent nerve roots or their branches. However, elevation of intraosseous pressure has also been implicated in the development and persistence of low back pain, while little evidence suggests an etiology for symptoms above the mid lumbar level. A degenerative process in the spine resulting in an intraosseous source of pain is plausible, given the observations made using peri-endplate magnetic resonance imaging (MRI) signal changes, demonstrating intraosseous edema, inflammation, or ischemic injury, and correlating with the region or site of clinical low back pain. Damage to the innervated vertebral endplates can reasonably result in vertebrogenic back pain (VBP) transmitted through branches of the basivertebral nerve (BVN), entering the posterior vertebral body and branching to superior and inferior endplates. Inflammation and edema noted at these sites have been implicated as the source of pain reflected by the enervating BVN. Radiofrequency ablation of the BVN via a percutaneous intraosseous approach has emerged as a possible interventional therapy for this condition. Current evidence suggests BVN ablation offers short- to intermediate-term improvements in function and pain. Prospective single-arm studies have reported clinically significant improvements in Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) from baseline, while Level 1 randomized controlled trials (RCTs) have demonstrated superiority over standard care at 3 months and 12 months and over sham control at 12 months. Diagnosis of vertebrogenic pain transmitted by the Basivertebral Nerve (BVN) is made by demonstration of Magnetic Resonance Imaging signal changes, either Modic 1 or Modic 2, in the affected vertebral body marrow, signifying inflammation, edema or ischemia, corresponding to the region of patient reported pain. Thermal destruction or ablation of the of the intraosseous Basivertebral Nerve (BVN) is a therapeutic surgical procedure projected to treat cLBP of a vertebrogenic origin only. The procedure uses fluoroscopic imaging to guide a thermal probe to the region of enervation in the vertebral body. Radiofrequency (RF) energy is applied to selectively destroy the BVN within the vertebral body. Concomitant paraspinal or paravertebral procedures or injections are excluded from coverage at the same session and same spinal region.

Coverage Indications, Contraindications, Medical Necessity, Non-Coverage and Limitations Covered Indications Thermal ablation of the intraosseous Basivertebral Nerve (BVN) is considered medically reasonable and necessary for the treatment of Chronic Low Back Pain (CLBP) in patient who meet ALL the following criteria for coverage and reimbursement. Individual is skeletally mature and has had CLBP for at least 6 months, with lower back pain as the dominant symptom. Has failed to adequately improve despite documented non-surgical management, to include at least 3 or more of the following modalities: Avoidance of activities that aggravate pain. Course of physical therapy or professionally directed therapeutic exercise program. Chiropractic manipulation Cognitive therapy Pharmacotherapy, including narcotic and non-narcotic analgesics, muscle relaxants, neuroleptics, and anti-inflammatories. Injection therapy of epidural or facet joint implicated pain sources in the region of concern Type 1 or Type 2 Modic changes on MRI: Endplate hypointensity (Type 1) or hyperintensity (Type 2) on T1 images plus hyperintensity on T2 images (Type1) involving the endplates between L3 and S1 Absence of additional vertebral pathology by physical, history, radiologic or clinical assessment including, but not limited to, fracture, tumor, infection, deformity, trauma, or post-surgical change which could cause the patient's symptoms or complicate the procedure and outcome. Physical and psychological assessment of patient’s ability to tolerate and benefit from BVN ablation. Contraindications to BVN Ablation, Medical Necessity and Non-Coverage The following conditions are considered relative contraindications to BVN ablation as suboptimal outcome and adverse exacerbation of symptoms may occur, precluding expected benefit from the procedure. Documentation in the patient’s medical record must explain the precautionary provisions taken for the individual patient to preclude anticipated or potential adverse events secondary to treatment. In the absence of documentation to support the procedure in individuals with the following concomitant conditions, medical necessity cannot be established. These conditions represent contraindication to treatment and render the service not medically appropriate, reasonable and necessary, or eligible for Medicare Coverage and Reimbursement. Skeletal immaturity ( Evidence on imaging (MRI, flexion/extension radiographs, CT) of another etiology for LBP symptoms, including, but not limited to, lumbar spinal stenosis, spondylolisthesis, segmental instability, disc herniation, degenerative scoliosis, facet arthropathy or effusion with clinically suspected facet joint pain. Metabolic bone disease (e.g., osteoporosis with T score -2.5), treatment of spine fragility fracture, trauma/compression fracture, or spinal primary or metastatic tumor. Active Spine or Systemic Infection Neurogenic claudication, lumbar radiculopathy, radicular pain, nerve impingement or compression (e.g., NHP, stenosis), as primary symptoms. Patients with severe cardiac or pulmonary compromise, systemic vulnerability to bleeding, or concern for further compromise of existing disease. Patients with implantable pulse generators (e.g., pacemakers, defibrillators, or neurostimulator) and other electronic implants, unless type specific precautions are taken to maintain patient safety. Ongoing use or abuse of addictive medications without evidence of potential weaning or decreased use with treatment. Limitations Basivertebral Nerve Ablation is limited to the following: No previous history of BVN ablation at the planned level of treatment. No more than one to two (1-2) vertebral bodies may be treated at a single session. Treatment of no more than 4 vertebral bodies per patient lifetime. Treatment is within the confines of L3-S1 vertebral bodies. Retreatment of a single vertebral body with BVN ablation within the patient's lifetime is not considered reasonable and necessary. Local anesthesia is considered appropriate for the region treated. Mild sedation may be administered by the performing physician or staff under his direction but should not be coded separately. Additional anesthesia services may not be billed separately without documentation of medical necessity. Definitions Chronic Pain/Chronic Low Back Pain : Pain lasting longer than six months in the same location, seemingly resistant to conservative measures. Conservative Measures/ Non-surgical Management : Any single or combination use of medication, physical therapeutic regimens, psychological or cognitive therapy designed by a qualified health care provider to affect relief of a disability or disease, based on a patient’s needs and physical findings. Incidental encounters are not considered therapeutic unless prescribed and monitored for defined purpose, time, and frequency by a qualified practitioner. Functional impairment : A physical, functional or physiologic impairment causing deviation from the normal function of a tissue, organ or body member, resulting in a significant limitation or impairment of the capacity to move, coordinate actions or perform physical activities, demonstrated by difficulty performing physical and motor tasks, independent movement or basic life functions. Modic Changes (Magnetic Resonance Imaging): MRI features consistent with Type 1 or Type 2 Modic changes such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change). Radicular pain or radiculopathy : pain radiating or identified in the path and distribution or dermatomal pattern of a named spinal nerve. Pain that is localized and does not travel in the distribution of an identified spinal nerve and remains axial in location is considered to have a non-radicular pattern. Spinal stenosis: Narrowing of the central spinal canal and /or the foraminal openings through which nerve or neural tissue are located, causing compression and irritation of the involved neural structures. A wide range of symptoms may be present, contributing to back and extremity pain and dysfunction.